Vycor Medical, Inc. (OTCQB:
VYCO) is changing and improving lives every day by providing the medical
community with innovative and superior surgical and therapeutic tools,
including a growing portfolio of FDA-cleared medical solutions. The company
currently operates two unique but complementary business units, Vycor Medical
and NovaVision, which adopt a minimally or non-invasive approach to a
collection of underserved medical applications.
Through its Vycor Medical unit,
the company designs, develops and markets the ViewSite Brain Access System
(VBAS), a proprietary suite of clear cylindrical disposable devices used to
gain access to specific neurological sites, such as tumors within the brain.
Vycor’s innovative medical instruments are designed to optimize neurosurgical
site access, reduce patient risk, accelerate recovery and add tangible value to
the professional medical community.
In recent months, the company
has made significant headway toward expanding VBAS’s presence within the
medical industry, increasing the number of U.S. hospitals for which the system
is approved to more than 190 during the first quarter of 2015. In large part,
this growth has come as a result of increasingly prevalent scientific data on
the system. According to a recently released study on VBAS published by
surgeons from Sapporo Medical University in Japan, the suite is believed to
provide a safer, more reliable, and less invasive method for the treatment of
deep-seated brain tumors.
“We continue to make good
progress with our VBAS product and the new studies we are anticipating this
year together with the launch of additional products makes me confident this
will translate into increased VBAS penetration and greater market acceptance
during the course of this year,” stated Peter Zachariou, chief executive
officer of Vycor, in a recent news release.
Through its NovaVision unit,
Vycor targets a substantial and largely unaddressed market of people who have
lost their sight as a result of stroke or traumatic brain injury. The company’s
family of therapies, which are clinically supported by decades of scientific
research, both restore and help to compensate for lost vision.
NovaVision’s unique product
offerings have gained significant industry traction in recent months. Late in
2014, the company received receipt of approval from HealthSouth to offer the
NovaVision VIDIT diagnostic device, and, earlier this month, Vycor continued on
this success by partnering with HealthSouth for a second time to make available
its NeuroEyeCoach Professional Center therapy program. These two agreements provide
the company with access to a potentially massive source of patients, as
HealthSouth is one of the largest providers of post-acute healthcare services
in the country.
“NovaVision is now positioned,
for the first time, with the suite of therapies and product offerings to
deliver on our strategic vision: to provide a clinically supported, affordable
and scalable visual therapy solution offering broad benefits to those suffering
from visual impairment following neurological damage,” continued Zachariou.
Moving forward, Vycor is in an
increasingly strong position to realize enhanced returns. Despite a slim
decrease in reported year-over-year revenue for the first quarter of 2015, the
company’s recently announced agreements with HealthSouth, as well as expanding
product approval rates for the VBAS, make Vycor an intriguing option for
prospective investors in the months to come.
For more information, visit
www.vycormedical.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
